Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casopitant + ondansetron
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Casopitant + ondansetron is a combination of two antiemetic drugs used together, often as part of triple regimens with corticosteroids like dexamethasone, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Casopitant is a selective, oral or intravenous neurokinin-1 (NK-1) receptor antagonist that inhibits substance P-mediated emetic signaling in the central nervous system. Ondansetron is a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist that blocks serotonin-mediated emetic signaling from the gut and CNS. The combination acts synergistically to improve prophylaxis of acute and delayed emesis related to moderately or highly emetogenic chemotherapy.
- Brand names
- ZofranZuplenz
- Other names
- casopitant + ondansetron
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on casopitant + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casopitant + ondansetron.